ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The correct management of CML patients is currently based on the serial quantitative molecular assessment of BCR-ABL1/ABL1 ratio, which results fundamental for continuing the same TKI (in patients with optimal response), changing drug (for failing cases) or for more strictly following cases with doubt or not stable response [104].